Erosive Osteoarthritis of the Hands: Treatment by Methotrexate Versus Placebo (ADEM)
Primary Purpose
Polyarthritis
Status
Unknown status
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
Methotrexate
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Polyarthritis
Eligibility Criteria
Inclusion Criteria:
- hand arthritis
- pain over 40/100
- stable treatment since 4 weeks at least with non-steroid analgesic
- between 45 et 85 years
Exclusion Criteria:
- pregnancy or breast feeding women
- hyaluronic acid injection within the past 6 months
- cortisonic derivated injection within the past 3 months
Sites / Locations
- Nice University Hospital, Rheumatology DepartmentRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Methotrexate
Placebo
Arm Description
Patients with digital arthritis receiving methotrexate treatment at 10mg/week during 12 months
Patients with digital arthritis receiving placebo at 10mg/week during 12 months
Outcomes
Primary Outcome Measures
pain assessed with EVA
Secondary Outcome Measures
Quality of life survey : SF-36
Full Information
NCT ID
NCT01068405
First Posted
January 12, 2010
Last Updated
December 8, 2011
Sponsor
Centre Hospitalier Universitaire de Nice
1. Study Identification
Unique Protocol Identification Number
NCT01068405
Brief Title
Erosive Osteoarthritis of the Hands: Treatment by Methotrexate Versus Placebo
Acronym
ADEM
Official Title
Erosive Osteoarthritis of the Hands: Treatment by Methotrexate Versus Placebo - Assessment of Structural and Clinical Action of Magnetic Resonance Imaging
Study Type
Interventional
2. Study Status
Record Verification Date
December 2011
Overall Recruitment Status
Unknown status
Study Start Date
March 2010 (undefined)
Primary Completion Date
March 2012 (Anticipated)
Study Completion Date
March 2012 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Nice
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Interest of methotrexate in inflammatory rheumatisms was demonstrated since several years.
At present time,there is no effective treatment against digital arthritis. The investigators purpose to measure the efficacy of methotrexate on digital arthritis.
In this aim, two groups were compared. The first group receive 10mg/week of methotrexate administered in one shot (every Monday for example)during 12 months. The second group receive 10mg/week of placebo according to the same procedure
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Polyarthritis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
64 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Methotrexate
Arm Type
Experimental
Arm Description
Patients with digital arthritis receiving methotrexate treatment at 10mg/week during 12 months
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Patients with digital arthritis receiving placebo at 10mg/week during 12 months
Intervention Type
Drug
Intervention Name(s)
Methotrexate
Intervention Description
Methotrexate: 10mg/week administered in one time, the same day each week (every monday for example)during 12 months
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo:10mg/week administered in one time, the same day each week (every monday for example)during 12 months
Primary Outcome Measure Information:
Title
pain assessed with EVA
Time Frame
at screening visit, inclusion visit, first month, and every month during one year
Secondary Outcome Measure Information:
Title
Quality of life survey : SF-36
Time Frame
at inclusion visit, first month, and every month during one year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
hand arthritis
pain over 40/100
stable treatment since 4 weeks at least with non-steroid analgesic
between 45 et 85 years
Exclusion Criteria:
pregnancy or breast feeding women
hyaluronic acid injection within the past 6 months
cortisonic derivated injection within the past 3 months
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Christian H ROUX, PhD
Email
roux.cr@chu-nice.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christian H ROUX, PhD
Organizational Affiliation
Nice University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Nice University Hospital, Rheumatology Department
City
Nice
ZIP/Postal Code
06000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian H ROUX, PhD
Phone
0492035491
Email
roux.cr@chu-nice.fr
12. IPD Sharing Statement
Citations:
PubMed Identifier
34157578
Citation
Ferrero S, Wittoek R, Allado E, Cruzel C, Fontas E, Breuil V, Ziegler L, Kremer J, Loeuille D, Roux CH. Methotrexate treatment in hand osteoarthritis refractory to usual treatments: A randomised, double-blind, placebo-controlled trial. Semin Arthritis Rheum. 2021 Aug;51(4):831-838. doi: 10.1016/j.semarthrit.2021.04.016. Epub 2021 May 6.
Results Reference
derived
PubMed Identifier
33501510
Citation
Allado E, Wittoek R, Albuisson E, Ferrero S, Chenuel B, Chary-Valckenaere I, Roux C, Loeuille D. Topographical analysis of structural lesions between dominant and non-dominant hands in erosive osteoarthritis. Rheumatol Int. 2021 Mar;41(3):617-623. doi: 10.1007/s00296-020-04784-1. Epub 2021 Jan 27.
Results Reference
derived
Learn more about this trial
Erosive Osteoarthritis of the Hands: Treatment by Methotrexate Versus Placebo
We'll reach out to this number within 24 hrs